Sarepta Therapeutics (SRPT) Stock News
$SRPT · NASDAQ · 3 stories in 30 daysBORSA has published 3 stories on Sarepta Therapeutics (SRPT) in the past 30 days. BORSA’s news read on SRPT is leaning bullish at 53/100, −1 over 24 hours, based on 3 company events over the past 30 days. Sarepta Therapeutics’ next earnings report is scheduled for Monday, Nov 2.
The wire on $SRPT
newest first · updated · direct subject stories onlySarepta to present new Duchenne gene therapy data at NMSG meeting
Sarepta will present seven posters at the 27th Annual Neuromuscular Study Group Scientific Meeting, including first results from the Phase 4 ENDURE study of delandistrogene moxeparvovec (ELEVIDYS) in Duchenne muscular dystrophy. The data will be presented on Sept. 25, 2026.
neutral 50 · impact 30